WGU D116 Advanced Pharmacology OA &
Actual Exam Prep 2026/2027: Verified
Questions with Detailed Clinical Rationales (A+
Graded Bundle)
Question 1
A 64-year-old male with a history of heart failure with reduced
ejection fraction (HFrEF) presents for a routine follow-up. He is
,currently taking lisinopril and carvedilol. The clinician decides to
transition the patient from lisinopril to sacubitril/valsartan (Entresto).
What is the mandatory washout period required between stopping
lisinopril and starting sacubitril/valsartan?
A) 12 hours
B) 24 hours
C) 36 hours
D) 48 hours
VERIFIED ANSWER: C) 36 hours
EXPLANATION: A 36-hour washout period is strictly required
when switching from an ACE inhibitor to an ARNI
(sacubitril/valsartan) to minimize the risk of severe angioedema.
Both ACE inhibitors and sacubitril inhibit the degradation of
bradykinin; concurrent presence or overlapping active levels of
these drugs can cause dangerous bradykinin accumulation. A
washout period is not required when switching from a standalone
ARB to an ARNI.
Question 2
A 45-year-old female patient is initiated on phenytoin for the
management of generalized tonic-clonic seizures. The clinician must
monitor serum levels closely due to phenytoin's unique metabolic
profile. Which statement best describes the pharmacokinetics of
,phenytoin?
A) It follows first-order kinetics across all serum concentration levels.
B) It changes from first-order to zero-order elimination kinetics as
metabolic enzymes saturate.
C) It has a highly predictable, linear dose-response relationship.
D) It is cleared entirely via renal excretion without undergoing
hepatic metabolism.
VERIFIED ANSWER: B) It changes from first-order to zero-order
elimination kinetics as metabolic enzymes saturate.
EXPLANATION: Phenytoin exhibits Michaelis-Menten (capacity-
limited or non-linear) kinetics. At low doses, elimination follows
first-order kinetics (proportional to dose). However, as serum
concentrations approach the therapeutic range (10-20 mcg/mL),
hepatic metabolic enzymes become saturated, shifting elimination to
zero-order kinetics. At this point, a very small increase in dosage
can lead to a disproportionately large and toxic increase in serum
concentration.
Question 3
A patient diagnosed with deep vein thrombosis (DVT) is prescribed
dabigatran. Which of the following mechanisms of action correctly
identifies how dabigatran exerts its anticoagulant effect?
A) Indirect inhibition of Factor Xa via antithrombin activation
, B) Direct and reversible inhibition of free and clot-bound thrombin
(Factor IIa)
C) Vitamin K epoxide reductase antagonism preventing factor
synthesis
D) Irreversible inhibition of cyclooxygenase-1 (COX-1) enzymes
VERIFIED ANSWER: B) Direct and reversible inhibition of free
and clot-bound thrombin (Factor IIa)
EXPLANATION: Dabigatran is an oral direct thrombin inhibitor
(DTI) that binds directly to the active site of thrombin (Factor IIa),
preventing the conversion of fibrinogen to fibrin. This differs from
direct Factor Xa inhibitors like rivaroxaban and apixaban, and
from warfarin, which targets vitamin K-dependent clotting factors
(II, VII, IX, X).
Question 4
A 32-year-old patient being treated for severe depression is prescribed
phenelzine, a Monoamine Oxidase Inhibitor (MAOI). The clinician
provides extensive dietary education to prevent a hypertensive crisis.
Which of the following foods must the patient strictly avoid?
A) Fresh green leafy vegetables and broccoli
B) Aged cheeses, cured meats, and red wine
C) Processed poultry and fresh white fish
D) Whole grain breads and citrus fruits
Actual Exam Prep 2026/2027: Verified
Questions with Detailed Clinical Rationales (A+
Graded Bundle)
Question 1
A 64-year-old male with a history of heart failure with reduced
ejection fraction (HFrEF) presents for a routine follow-up. He is
,currently taking lisinopril and carvedilol. The clinician decides to
transition the patient from lisinopril to sacubitril/valsartan (Entresto).
What is the mandatory washout period required between stopping
lisinopril and starting sacubitril/valsartan?
A) 12 hours
B) 24 hours
C) 36 hours
D) 48 hours
VERIFIED ANSWER: C) 36 hours
EXPLANATION: A 36-hour washout period is strictly required
when switching from an ACE inhibitor to an ARNI
(sacubitril/valsartan) to minimize the risk of severe angioedema.
Both ACE inhibitors and sacubitril inhibit the degradation of
bradykinin; concurrent presence or overlapping active levels of
these drugs can cause dangerous bradykinin accumulation. A
washout period is not required when switching from a standalone
ARB to an ARNI.
Question 2
A 45-year-old female patient is initiated on phenytoin for the
management of generalized tonic-clonic seizures. The clinician must
monitor serum levels closely due to phenytoin's unique metabolic
profile. Which statement best describes the pharmacokinetics of
,phenytoin?
A) It follows first-order kinetics across all serum concentration levels.
B) It changes from first-order to zero-order elimination kinetics as
metabolic enzymes saturate.
C) It has a highly predictable, linear dose-response relationship.
D) It is cleared entirely via renal excretion without undergoing
hepatic metabolism.
VERIFIED ANSWER: B) It changes from first-order to zero-order
elimination kinetics as metabolic enzymes saturate.
EXPLANATION: Phenytoin exhibits Michaelis-Menten (capacity-
limited or non-linear) kinetics. At low doses, elimination follows
first-order kinetics (proportional to dose). However, as serum
concentrations approach the therapeutic range (10-20 mcg/mL),
hepatic metabolic enzymes become saturated, shifting elimination to
zero-order kinetics. At this point, a very small increase in dosage
can lead to a disproportionately large and toxic increase in serum
concentration.
Question 3
A patient diagnosed with deep vein thrombosis (DVT) is prescribed
dabigatran. Which of the following mechanisms of action correctly
identifies how dabigatran exerts its anticoagulant effect?
A) Indirect inhibition of Factor Xa via antithrombin activation
, B) Direct and reversible inhibition of free and clot-bound thrombin
(Factor IIa)
C) Vitamin K epoxide reductase antagonism preventing factor
synthesis
D) Irreversible inhibition of cyclooxygenase-1 (COX-1) enzymes
VERIFIED ANSWER: B) Direct and reversible inhibition of free
and clot-bound thrombin (Factor IIa)
EXPLANATION: Dabigatran is an oral direct thrombin inhibitor
(DTI) that binds directly to the active site of thrombin (Factor IIa),
preventing the conversion of fibrinogen to fibrin. This differs from
direct Factor Xa inhibitors like rivaroxaban and apixaban, and
from warfarin, which targets vitamin K-dependent clotting factors
(II, VII, IX, X).
Question 4
A 32-year-old patient being treated for severe depression is prescribed
phenelzine, a Monoamine Oxidase Inhibitor (MAOI). The clinician
provides extensive dietary education to prevent a hypertensive crisis.
Which of the following foods must the patient strictly avoid?
A) Fresh green leafy vegetables and broccoli
B) Aged cheeses, cured meats, and red wine
C) Processed poultry and fresh white fish
D) Whole grain breads and citrus fruits
